Atty #11

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	8

Complete if Known	
Application Number	**09/782,721**
Filing Dat	**February 12, 2001**
First Named Inv ntor	**H. Michael SHEPARD**
Art Unit	1623 ~~1653~~
Examiner Name	**L. Crane**
Attorney Docket Number	**NB 2004.02**

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number – Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,247,544	01-27-81	Bergstrom, et al.	
	2	US-4,267,171	04-12-81	Bergstrom, et al.	
	3	US-4,542,210	09-17-85	Sakata et al.	
	4	US-4,816,570	03-28-89	Farquhar	
	5	US-4,948,882	08-14-90	Ruth	
	6	US-4,975,278	12-04-90	Senter et al.	
	7	US-5,085,983	02-04-92	Scanlon	
	8	US-5,233,031	08-03-92	Borch et al.	
	9	US-5,264,618	11-23-93	Felgner et al.	
	10	US-5,459,127	10-17-85	Felgner et al.	
	11	US-5,521,161	05-28-96	Malley et al.	
	12	US-5,627,165	05-06-97	Glazier	
	13	US-5,645,988	07-08-97	Vande Woude et al.	
	14	US-5,663,321	09-02-97	Gmeiner et al.	
	15	US-5,798,340	08-25-98	Bischofberger et al.	
	16	US-5,981,507	11-09-99	Josephson et al.	

COPY OF PAPERS ORIGINALLY FILED

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document – Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
~~**~~	~~17~~	~~GB 982 776~~	02/10/65	The Wellcome Foundation		
	18	WO 91/17424	11/14/91	Vical, Inc.		
	19	WO 94/03467	02/17/94	Institute of Organic Chemistry & Biochemistry of the Academy of Sciences of the Czech Republic, Rega Stichting VZW and Gilead Sciences, Inc.		
	20	WO 96/29336	06/26/96	Amersham International, PLC		
	21	WO 96/40088	12/19/96	Hostetler, Karl		
~~**~~	~~22~~	~~WO 97/28179~~	~~08/07/97~~	Fick, James & Israel, Mark		

** Duplicate: see pto-892 for citation of record.

Sheet 2	of	Attorney Docket Number	NB 2004.02

	23	WO 99/23118	05/14/99	The Government of the United States of American represented by The Secretary of Health & Human Services		

Examiner's Signature	L. E. Crane	Date Considered	08/20/02	

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 8

Complete if Known	
Application Number	09/782,721
Filing Date	February 12, 2001
First Named Inventor	H. Michael Shepard
Art Unit	1623 ~~1653~~
Examiner Name	L. Crane
Attorney Docket Number	NB 2004.02

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	24 !	Abraham et al., "Synthesis and biological activity of aromatic amino acid phosphoramidates of 5-fluoro-2'-deoxyuridine and 1-*J*-arabinofuranosylcytosine: Evidence of phosphoramidase activity" *J. Med. Chem. 39*:4569-4575 (1996).	
	25 !	Akdas et al., "Glutathione S-transferase and multidrug-resistant phenotype in transitional cell carcinoma of the bladder" *Eur. Urol. 29*(4):483-486 (1996).	
	26 !	Almasan et al., "Genetic instability as a consequence of inappropriate entry into and progression through S-phase" *Can. Metastasis Rev. 14*:59-73 (1995).	
	27 !	Andersen et al., "Detection of c-erbb-2 related protein in sera from breast cancer patients" *Acta Oncol. 34*(4):499-504 (1995).	
	28 !	Anglada et al., "*N,N'*-cyclization of carbodiimides with 2-(bromomethyl)acrylic acid. A direct entry to the system 5-methylene-6*H*-pyrimidine-2,4-dione, A new class of thymine analogues" *J. Heterocycl. Chem. 33*:1259-1270 (1996).	
	29 !	Antelman et al., "Inhibition of tumor cell proliferation *in vitro* and *in vivo* by exogenous p110RB, the retinoblastoma tumor suppressor protein" *Oncogene 10*:697-704 (1995).	
	30 !	Asakura et al., "Cerium(IV) catalyzed iodination at C5 of uracil nucleosides" *Tetrahedron Lett. 29*(23):2855-2858 (1988).	
	31 !	Asakura et al., "Cerium(IV)-mediated halogenation at C-5 of uracil derivatives" *J. Org. Chem. 55*:4928-4933 (1990).	
	32 !	Ayisi et al. "Comparison of the antiviral effects of 5-methoxymethyldeoxyuridine-5'-monophosphate with adenine arabinoside-5'-monophosphate" *Antivirals Res.* 3:161-174 (1983)	
	33 !	Balzarini et al., "Incorporation of 5-substituted pyrimidine nucleoside analogues into DNA of a thymidylate synthetase-deficient murine FM3A carcinoma cell line" *Meth. Find. Exp. Clin. Pharmacol. 7*(1):19-28 (1985).	
	34 !	Balzarini, J. et al., "Thymidylate synthase is the principal target enzyme for the cytostatic activity of (*E*)-5-(2-bromovinyl)-2'-deoxyuridine against murine mammary carcinoma (FM3A) cells transformed with the herpes simplex virus type 1 or type 2 thymidine kinase gene" *Mol. Pharmacol. 32*:410-416 (1987).	
	35 !	Balzarini et al., "Differential mechanism of cytostatic effect of (*E*)-5-(2-bromovinyl)-2'-deoxyuridine , 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2" *J. Biol. Chem. 268*(9):6332-6337 (1993).	
	36 !	Balzarini et al., "Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109" *Biochem. Biophys. Res. Commun. 225*:363-369 (1996).	
	37 !	Balzarini et al., "Conversion of 2',3'-dideoxyadenosine (ddA) and 2',3'-didehydro-2',3'-dideoxyadenosine (d4A) to their corresponding aryloxyphosphoramidate derivatives markedly potentiates their activity against human immunodeficiency virus and hepatitis B virus" *FEBS Lett. 410*:324-328 (1997).	
	38 !	Banerjee et al., "Molecular mechanisms of resistance to antifolates, a review" *Acta Biochem. Pol. 42*(4):457-464 (1995).	
	39 !	Banerjee et al., "Role of E2F-1 in chemosensitivity" *Can. Res. 58*:4292-4296 (1998).	
	40 !	Barbour et al., "A naturally occurring tyrosine to histidine replacement at residue 33 of human thymidylate synthase confers resistance to 5-fluoro-2'-deoxyuridine in mammalian and bacterial cells" *Mol. Pharmacol. 42*:242-248 (1992).	
	41 !	Barr, "Inhibition of thymidylate synthetase by 5-alkynyl-2'-deoxyuridylates" *J. Med. Chem. 24*(12):1385-1388 (1981).	
	42 !	Barr et al., "Thymidylate synthetase-catalyzed conversions of *E*-5-(2-bromovinyl)-2'-deoxyuridylate" *J. Biol. Chem. 258*(22):13627-13631 (1983).	
	43 !	Barr et al., "Reaction of 5-ethynyl-2'-deoxyuridylate with thiols and thymidylate synthetase" *Biochem. 22*:1696-1703 (1983).	
	44 !	Barrett, "Trapping of the C5 methylene intermediate in thymidylate synthase" *J. Am. Chem. Soc. 120*:449-450 (1998).	
	45 !	Benzaria et al., "Synthesis, *in vitro* antiviral evaluation, and stability studies of bis(*S*-acyl-2-thioethyl) ester derivatives of 9-[2-(phosphonomethoxy)ethyl]adenine (PMEA) as potential PMEA prodrugs with improved oral bioavailability" *J. Med. Chem. 39*:4958-4965 (1996).	
	46 !	Bergstrom et al., "C-5-substituted pyrimidine nucleosides. 3. Reaction of allylic chlorides, alcohols, and acetates with pyrimidine nucleoside derived organopalladium intermediates" *J. Org. Chem. 46*(7):1432-1441 (1981).	
	47 !	Bergstrom et al., "Synthesis of (*E*)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine and related analogues: Potent and unusually selective antiviral activity of (*E*)-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridine against herpes simplex virus type 1" *J. Med. Chem. 27*:279-284 (1984).	
	48 !	Bertino et al., "Resistance mechanisms to methotrexate in tumors" *Stem Cells 14*:5-9 (1996).	

! Month of publication data is unavailable for this citation.

OTHER PRIOR ART – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	49 !	Bigge et al., "Palladium-catalyzed coupling reactions of uracil nucleosides and nucleotides" *J. Amer. Chem. Soc. 102*:2033-2038 (1980).	
	50 !	Bosslet t al., "A novel one-step tumor-selective prodrug activation system" *Tumor Targeting 1*:45-50 (1995).	
	51 !	Bosslet et al., "Elucidation of the mechanism enabling tumor selective prodrug monotherapy" *Can. Res. 58*:1195-1201 (1998).	
	52 !	Brison, "Gene amplification and tumor progression" *Biochem. Biophys. Acta 1155*:25-41 (1993).	
	53 !	Carl et al., "Protease-activated 'prodrugs' for cancer chemotherapy" *PNAS USA 77*(4):2224-2228 (1980).	
	54 !	Carreras et al., "The catalytic mechanism and structure of thymidylate synthase" *Ann. Rev. Biochem. 64*:721-762 (1995).	
	55 !	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" *PNAS USA 89*:4285-4289 (1992).	
	56 !	Cava et al., "Thionation reactions of lawesson's reagents" *Tetrahedron 41*(22):5061-5087 (1985).	
	57 !	Chakravarty et al., "Plasmin-activated prodrugs for cancer chemotherapy. 2. Synthesis and biological activity of peptidyl derivatives of doxorubicin" *J. Med. Chem. 26*(5):638-644 (1983).	
	58 !	Chaudhuri et al., "Very high affinity DNA recognition by bicyclic and cross-linked oligonucleotides" *J. Am. Chem. Soc. 117*:10434-10442 (1995).	
	59 !	Chen et al., "Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P450 gene" *Can. Res. 56*:1331-1340 (1996).	
	60 !	Cho et al., "(*E*)-5-(3-oxopropen-1-yl)-2'-deoxyuridine and (*E*)-5-(3-oxopropen-1-yl)-2',3'-dideoxyuridine; New antiviral agents: Synthesis and biological activity" *Tetrahedron Lett. 35*(8):1149-1152 (1994).	
	61 !	Clarke, "Animal models of breast cancer: Their diversity and role in biomedical research" *Breast Can. Res. Treat. 39*:1-6 (1996).	
	62 !	Colacino, "Mechanisms for the anti-hepatitis B virus activity and mitochondrial toxicity of fialuridine (FIAU)" *Antiviral Res. 29*:125-139 (1996).	
	63	Collins, J.M. et al. "Suicide prodrugs activated by Thymidylate synthase: Rationale for treatment and noninvasive imaging of tumors with deoxyuridine analogues" *Clin. Cancer Res.* 5:1976-1981 (August 1999)	
	64 !	Connors, "Prodrugs in cancer chemotherapy" *Xenobiotica 16*(10/11):975-988 (1986).	
	65 !	Connors, et al., "Prodrugs in cancer chemotherapy" *Stem Cells 13*:501-511 (1995).	
	66 !	Connors, "Is there a future for cancer chemotherapy?" *Annals Oncol. 7*:445-452 (1996).	
	67 !	Copur et al., "Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil" *Biochem. Pharmacol. 49*(10):1419-1426 (1995).	
	68 !	Crisp, "Synthesis of 5-alkenyl-2'-deoxyuridines via organostannanes" *Synth. Commun. 19*(11 & 12):2117-2123 (1989).	
	69 !	Dale et al., "The synthesis and enzymatic polymerization of nucleotides containing mercury: Potential tools for nucleic acid sequencing and structural analysis" *PNAS USA 70*(8):2238-2242 (1973).	
	70 !	Davisson et al., "Expression of human thymidylate synthase in *Escherichia coli*" *J. Biol. Chem. 264*(16):9145-9148 (1989).	
	71 !	Davisson et al. "Expression of human thymidylate synthase in *Escherichia coli*. (Additions and corrections)" *J. Biol. Chem. 269*(48):30740 (1994).	
	72 !	De Clercq et al., "Nucleic acid related compounds. 40. Synthesis and biological activities of 5-alkynluracil nucleosides" *J. Med. Chem. 26*:661-666 (1983).	
	73 !	Dicker et al., "Methotrexate resistance in an *in vivo* mouse tumor due to a non-active-site dihydrofolate reductase mutation" *PNAS USA 90*:11797-11801 (1993).	
	74 !	Dirven et al., "The role of human glutathione *S*-transferase isoenzymes in the formation of glutathione conjugates of the alkylating cytostatic drug thiotepa" *Can. Res. 55*:1701-1706 (1995).	
	75 !	Dorr et al., "PALA" *In*: Cancer Chemotherapy Handbook: Appleton & Lange, Norwalk, Connecticut:768-773 (1994).	
	76 !	Dunn et al., "Solution of the conformation and alignment tensors for the binding of trimethoprim and its analogs to dihydrofolate reductase: 3D-quantitative structure-activity relationship study using molecular shape analysis, 3-way partial least-squares regression, and 3-way factor analysis" *J. Med. Chem. 39*:4825-4832 (1996).	
	77 !	Dyer et al., "Nucleic Acids Chemistry: Improved and new synthetic procedures, methods, and techniques" Townsend, L. B. & Tipson, R. S., eds. (Wiley-Interscience, New York, NY) Vol. 4:79-83 (1991).	
	78 !	Eccles et al., "Significance of the c-*erbB* family of receptor tyrosine kinases in metastatic cancer and their potential as targets for immunotherapy" *Invasion Metastasis 14*(1-6):337-348 (1994-95).	
	79 !	Eisenbrand et al., "An approach towards more selective anticancer agents" *J. Synthetic Organic Chem. 10*:1246-1258 (1996).	
	80 !	Evard, A. et al. "An in vitro nucleoside analog screening method for cancer gene therapy" *Chem. Abstracts 126*:Abstract No. 26514 (1996)	
	81 !	Farquhar et al., "Synthesis and antitumor evaluation of bis[(pivaloyloxy)methyl] 2'-deoxy-5-fluorouridine 5'-monophosphate (FdUMP): A strategy to introduce nucleotides into cells" *J. Med. Chem. 37*:3902-3909 (1994).	
	82 !	Farquhar et al., "5'-[4-pivaloyloxy)-1,3,2-dioxaphosphorinan-2-yl]-2'-deoxy-5-fluorouridine: A membrane-permeating prodrug of 5-fluoro-2'-deoxyuridylic acid (FdUMP)" *J. Med. Chem. 38*:488-495 (1994).	
	83 !	Felip et al., "Overexpression of c-*erbB*-2 in epithelial ovarian cancer" *Cancer 75*(8):2147-2152 (1995).	
	84 !	Finch et al., "Radiation Injury" *In*: Harrison's Principles of Internal Medicine, 12th edition: McGraw-Hill, Inc., New York, NY:2204-2208 (1991).	

! Month of publication data is unavailabe for this citation.

OTHER PRIOR ART – NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
JKE	85 !	Finer-Moore et al., "Refined structures of substrate-bound and phosphate-bound thymidylate synthase from *Lactobacillus casei*" *J. Mol. Biol. 232*:1101-1116 (1993).	
JKE	86 !	Finer-Moore et al., "Crystal structure of thymidylate synthase from T4 phage: Component of a deoxynucleoside triphophate-synthesizing complex" *Biochem. 33*:15459-15468 (1994).	
JKE	87 !	Firestone et al., "A comparison of the effects of antitumor agents upon normal human epidermal kerarinocytes and human squamous cell carcinoma" *Chem Abstracts 113*:Abstract No. 254 (1990)	
JKE	88 !	Freed et al., "Evidence for acyloxymethyl esters of pyrimidine 5'-deoxyribonucleotides as extracellular sources of active 5'-deoxyribonucleotides in cultured cells" *Biochem. Pharmacol. 38*(19):3193-3198 (1989).	
JKE	89 !	Fries et al., "Synthesis and biological evaluation of 5-fluoro-2'-deoxyuridine phosphoramidate analogs" *J. Med. Chem. 38*(14):2672-2680 (1995).	
JKE	90 !	Garrett et al., "Thymidylate synthetase. Catalysis of dehalogenation of 5-bromo-and 5-iodo-2'-deoxyuridylate" *Biochem. 18*(13):2798-2804 (1979).	
JKE	91 !	Goldberg et al. "Novel cell imaging techniques show induction of apoptosis and proliferation in mesothelial cells by asbestos" *Am. J. Respir. Cell Mol. Biol.* 17:265-271 (1997)	
JKE	92 !	Goldstein et al., "Genetic aspects of disease" *In*: Harrison's Principles of Internal Medicine, 12th edition: McGraw-Hill, Inc., New York, NY:21-76 (1991).	
JKE	93 !	Goodwin et al., "Incorporation of alkylthiol chains at C-5 of deoxyuridine" *Tetrahedron Lett. 34*(35):5549-5552 (1993).	
JKE	94 !	Gottesmanm et al., "Genetic analysis of the multidrug transporter" *Ann. Rev. Gen. 29*:607-649 (1995).	
JKE	95 !	Graham et al., "DNA duplexes stabilized by modified monomer residues: Synthesis and stability" *J. Chem. Soc. Perkin Trans. 1*:1131-1138 (1998).	
JKE	96 !	Gros et al., "Isolation and expression of a complementary DNA that confers mutidrug resistance" *Nature 323*:728-731 (1986).	
JKE	97 !	Gros et al., "Mammalian mutidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport proteins" *Cell 47*:371-380 (1986).	
JKE	98 !	Gros et al., "Isolation and characterization of DNA sequences amplified in multidrug-resistant hamster cells" *PNAS USA 83*:337-341 (1986).	
JKE	99 !	Gudkov et al., "Cloning and characterization of DNA sequences amplified in multidrug-resistant djungarian hamster and mouse cells" *Somat. Cell Mol. Genet. 13*(6):609-619 (1987).	
JKE	100 !	Hardy et al., "Atomic structure of thymidylate synthase: Target for rational drug design" *Science 235*:448-455 (1987).	
JKE	101 !	Harris et al., "Adenovirus-mediated p53 gene transfer inhibits growth of human tumor cells expressing mutant p53 protein" *Can. Gene Ther. 3*(2):121-130 (1996).	
JKE	102 !	Hashimoto et al., "Simple separation of tritiated water and [3H] deoxyuridine from [5-3H] deoxyuridine 5'-monophosphate in the thymidylate synthase assay" *Anal. Biochem. 167*:340-346 (1987).	
JKE	103 !	Hengstschläger et al., "The role of p16 in the E2F-dependent thymidine kinase regulation" *Oncogene 12*:1635-1643 (1996).	
JKE	104 !	Hobbs, "Palladium-catalyzed synthesis of alkynylamino nucleosides. A universal linker for nucleic acids" *J. Org. Chem. 54*:3420-3422 (1989).	
JKE	105 !	Horikoshi et al., "Quantitation of thymidylate synthase, dihydrofloate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction" *Can. Res. 52*:108-116 (1992).	
JKE	106 !	Horn et al., "Fialuridine is phosphorylated and inhibits DNA synthesis in isolated rat hepatic mitochondria" *Antiviral Res. 34*:71-74 (1997).	
JKE	107 !	Hostetler et al., "Enhanced oral absorption and antiviral activity of 1-o-octadecyl-*sn*-glycero-3-phospho-acyclovir and related compounds in hepatitis B virus infection, *in vitro*" *Biochem. Pharmacol. 53*:1815-1822 (1997).	
JKE	108 !	Houze, "Detection of thymidylate synthase gene expression levels in formalin-fixed paraffin embedded tissue by semiquantitative, nonradioactive reverse transcriptase polymerase chain reaction" *Tumor Biol. 18*:53-68 (1997).	
JKE	109 !	Hsaio et al., "Synthesis of 5'-thymidinyl bis(1-aziridinyl)phosphinates as antineoplastic agents" *J. Med. Chem. 24*:887-889 (1981).	
JKE	110 !	Huang et al., "Active site general catalysts are not necessary for some proton transfer reactions of thymidylate synthase" *Biochem. 36*:1869-1873 (1997).	
JKE	111 !	Hudziak et al., "Amplified expression of the HER2/ERBB2 oncogene induces resistance to tumor necrosis factor I in NIH 3T3 cells" *PNAS USA 85*:5102-5106 (1988).	
JKE	112 !	Hudziak et al., "Selection for transformation and *met* protooncogene amplification in NIH 3T3 fibroblasts using tumor necrosis factor I" *Cell Growth & Differentiation 1*:129-134 (1990).	
JKE	113 !	Husak, R. et al. "Pseudotumour of the tongue caused by herpes simplexx virus type 2 in an HIV-1 infected immunosuppressed patient" *British J. Dermatol.* 139:118-121 (1998)	
JKE	114 !	Imai et al., "Studies on phosphorylation. IV. Selective phosphorylation of the primary hydroxyl group in nucleosides" *J. Org. Chem. 34*(6):1547-1550 (1969).	
JKE	115 !	Jackman et al., "Quinazoline-based thymidylate synthase inhibitors: Relationship between structural modifications and polyglutamation" *Anti-Cancer Drug Design 10*:573-589 (1995).	
JKE	116 !	Johnston et al., "Production and characterization of monoclonal antibodies that localize human thymidylate synthase in the cytoplasm of human cells and tissue" *Can. Res. 51*:6668-6676 (1991).	
JKE	117 !	Johnston, "The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer" *J. Clin. Oncol. 12*(12):2640-2647 (1994).	
JKE	118 !	Kamb et al., "Cyclin-dependent kinase inhibitors and human cancer" *Curr. Top. Microbiol. Immunol. 227*:139-148 (1998).	
JKE	119 !	Kashani-Sabet et al., "Detection of drug resistance in human tumors by *in vitro* enzymatic amplification" *Can. Res. 48*:5775-5778 (1988).	

! Month of publication data is unavailable for this citation.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	120	Katki, A.G. et al. "Prodrugs activated by thymidylate synthase: Treatment of tumors with deoxyuridine analogs" *Proc. Amer. Assoc. Cancer Res.* 39, Abstract No. 1275 (March 1998)	
	121 !	Klecker et al., "Toxicity, metabolism, DNA incorporation with lack of repair, and lactate production for 1-(2'-fluoro-2'-deoxy-J-D-arabinofuranosyl)-5-iodouracil in U-937 and MOLT-4 cells" *Mol. Pharmacol. 46*:1204-1209 (1994).	
	122 !	Knighton et al., "Structure and kinetic channelling in bifunctional dihydrofolate reductase-thymidylate synthase" *Nature Struct. Biol. 1*(3):186-194 (1994).	
	123 !	Kobayashi et al., "Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors" *Jpn. J. Can. Res. 86*:1014-1018 (1995).	
	124 !	Kodama, E. et al. "Evaluation of antiherpetic compounds using a gastric cancer cell line: Pronounced activity of BVDU against herpes simplex virus replication" *Microbiol. Immunol.* 40(5):359-363 (1996)	
	125 !	Kumar et al., "Synthesis and biological evaluation of some cyclic phosphoramidate nucleoside derivatives" *J. Med. Chem. 33*(9):2368-2735 (1990).	
	126 !	Kundu, "Synthesis and biological activities of [E]-5-(2-acylvinyl) uracils" *Eur. J. Med. Chem. 28*:473-479 (1993).	
	127 !	Kuroboshi et al., "A facile synthesis of difluoromethylene compounds by oxidative fluorodesulfurization of dithioacetals using tetrabutylammonium dihydrogentrifluoride and *N*-halo compounds" *SYNLETT*:909-910 (1991).	
	128 !	Kuroboshi et al., "A facile synthesis of l,l-difluoroalkyl ethers and carbonyl fluoride acetals by oxidative desulfurization-fluorination" *SYNLETT*:251-252 (1994).	
	129 !	Lam, "Application of combinatorial library methods in cancer research and drug discovery" *Anticancer Drug Design 12*:145-167 (1997).	
	130 !	Larsson, P.A., et al. "Thymidylate synthase in advanced gastrointestinal and breast cancers" *Acta Oncologica* 35(4):469-472 (1996)	
	131 !	Lasic, "Doxorubicin in sterically stabilized liposomes" *Nature 380*:561-562 (1996).	
	132 !	Lewis et al., "A serum-resistant cytofection for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA" *PNAS USA. 93*:3176-3181 (1996).	
	133 !	Li et al., "Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines" *PNAS USA 92*:10436-10440 (1995).	
	134 !	Lin et al., "Rhenium-188 hydroxyethylidene diphosphonate: A new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases" *Eur. J. Nucl. Med. 24*(6):590-595 (1997).	
	135 !	Livak et al., "Detection of single base differences using biotinylated nucleotides with very long linker arms" *Nucl. Acids Res. 20*(18):4831-4837 (1992).	
	136 !	Livingstone, L.R. et al., "Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53" *Cell 70*:923-935 (1992).	
	137 !	Lönn et al., "Higher frequency of gene amplification in breast cancer patients who received adjuvant chemotherapy" *Cancer 77*(1):107-112 (1996).	
	138 !	Lovejoy et al., "Animal models and the molecular pathology of cancer" *J. Pathol. 181*:130-135 (1997).	
	139 !	Masters et al., "The nucleotide sequence of the cDNA coding for the human dihydrofolic acid reductase" *Gene 21*:59-63 (1983).	
	140 !	McGuigan, "Aryl phosphate derivatives of AZT retain activity HIV1 in cell lines which are resistant to the action of AZT" *Antiviral Res. 17*:311-321 (1992)	
	141 !	McGuigan, "Intracellular delivery of bioactive AZT nucleotides by aryl phosphate derivatives of AZT" *J. Med. Chem. 36*:1048-1052 (1993)	
	142 !	McGuigan et al., "Certain phosphoramidate derivatives of dideoxy uridine (ddU) are active against HIV and successfully by-pass thymidine kinase" *FEBS Let 351*:11-14 (1994)	
	143 !	McGuigan, "Aryl phosphoramidate derivatives of d4T have improved anti-HIV efficacy in tissue culture and may act by the generation of a novel intracellular metabolite" *J. Med. Chem. 39*:1748-1753 (1996).	
	144 !	McGuigan et al., "Synthesis and evaluation of some masked phosphate esters of the anti-herpetic drug 882C (netivudine) as potential antiviral agents" *Antiviral Chem. Chemother. 9*:187-197 (1998).	
	145 !	McIntee, "Probing the mechanism of action and decomposition of amino acid phosphomonoester amidates of antiviral nucleoside prodrugs" *J. Med. Chem. 40*:3323-3331 (1997).	
	146 !	McKay et al., "Broad spectrum aminoglycoside phosphotransferase type III from *Enterococcus*: Overexpression, purification, and substrate specificity" *Biochem 33*:6936-6944 (1994).	
	147 !	Meden et al., "Elevated serum levels of a c-erbB-2 oncogene product in ovarian cancer patients and in pregnancy" *J. Can. Res. Clin. Oncol. 120*:378-381 (1994).	
	148 !	Meier et al., "ADA-bypass by lipophilic *cyclo*sal-ddAMP pro-nucleotides a second example of the efficiency of the *cyclo*sal-concept" *Bioorg. Med. Chem. Lett. 7*(12):1577-1582 (1997).	
	149 !	Meier et al., "Cyclic saligenyl phosphotriesters of 2',3'-dideoxy-2',3'-didehydrothymidine (d4T)- a new pro-nucleotide approach" *Bioorg. Med. Chem. Lett. 7*(2):99 (1997).	
	150 !	Meier et al., "*Cyclo*Sal-pro-nucleotides: The design and biological evaluation of a new class of lipophilic nucleotide prodrugs" *Int'l. Antiviral News 5*(10):183-185 (1997).	
	151 !	Melton et al., "Antibody-enzyme conjugates for cancer therapy" *J. Natl. Can. Inst. 88*(3/4):153-165 (1996).	
	152 !	Montfort et al., "Thymidylate synthase: Structure, inhibition, and strained conformations during catalysis" *Pharmacol. Ther. 76*(1-3):29-43 (1997).	
	153 !	Montgomery et al., "Phosphonate analogue of 2!-deoxy-5-fluorouridylic acid" *J. Med. Chem. 22*(1):109-111 (1979).	
	154 !	Morgan et al., "Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione *S*-transferase" *Can. Res. 58*:2568-2575 (1998).	
	155 !	Murakami et al., "Accumulation of genetic alterations and their significance in each primary human cancer and cell line" *Mutat. Res. 400*(1-2):421-437 (1998).	

! Month of publication data is unavailable for this citation.

COPY OF PAPERS ORIGINALLY FILED

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	156	Nakano et al., "Critical role of phenylalanine 34 of human dihydrofolate reductase in substrate and inhibitor binding and in catalysis" *Biochem. 33*:9945-9952 (1994).	
	157	Nooter et al., "Molecular mechanisms of multidrug resistance in cancer chemotherapy" *Pathol. Res. Pract. 192*:768-780 (1996).	
	158	Osaki et al., "5-fluorouracil (5-FU) induced apoptosis in gastric cancer cell lines: Role of the p53 gene" *Apoptosis 2*:221-226 (1997).	
	159	Oshiro, Y. et al. "Genotoxic properties of *(E)*-5-(2-bromovinyl)-2'-deoxyuridine (BVDU)" *Fund. Appl. Toxicol.* 18:491-498 (1992)	
	160	Pardo et al. "The incorporation of deoxyuridine monophosphate in DNA increases the sister-chromatid exchange yield" *Exp Cell Res.* 168:507-517 (1987)	
	161	Park, N.H. et al. "Chemotherapy efficacy of E-5-(2-bromovinyl)-2'-deoxyuridine for orofacial infection with herpes simplex virus type 1 in mice" *J. Infectious Diseases* 145(6):909-913 (1982)	
	162	Perry et al. "Plastic adaptation toward mutations in proteins: Structural comparison of thymidylate synthases" *Proteins 8*:315-333 (1990).	
	163	Pestalozzi et al., "Prognostic importance of thymidylate synthase expression in early breast cancer" *J. Clin. Oncol. 15*(5):1923-1931 (1997).	
	164	Peters et al., "Thymidylate synthase and drug resistance" *Eur. J. Can. 31A*(7/8):1299-1305 (1995).	
	165	Phelps et al., "Synthesis and biological activity of 5-fluoro-2'-deoxyuridine 5'-phosphorodiamidates" *J. Med. Chem. 23*:1229-1232 (1980).	
	166	Pupa et al., "The extracellular domain of the c-*erb*B-2 oncoprotein is released from tumor cells by proteolytic cleavage" *Oncogene 8*:2917-2923 (1993).	
	167	Roberts, "An isotopic assay for thymidylate synthetase" *Biochem. 5*(11):3546-3548 (1966).	
	168	Robins et al., "Nucleic acid related compounds. 31. Smooth and efficient palladium-copper catalyzed coupling of terminal alkynes with 5-iodouracil nucleosides" *Tetrahedron Lett. 22*:421-424 (1981).	
	169	Robins et al., "Nucleic acid related compounds. 38. Smooth and high-yield iodination and chlorination at C-5 of uracil bases and *p*-toluyl-protected nucleosides" *Can. J. Chem. 60*:554-557 (1982).	
	170	Robins et al., "Nucleic acid compounds. 39. Efficient conversion of 5-iodo to 5-alkynyl and derived 5-substituted uracil bases and nucleosides" *J. Org. Chem. 48*:1854-1862 (1983).	
	171	Rogulski, K.R. et al. "Glioma cells transduced with an *Escherichia coli* CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity" *Hum. Gene Ther.* 8:73-85 (1997)	
	172	Roninson et al., "Amplification of specific DNA sequences correlates with multi-drug resistance in chinese hamster cells" *Nature 309*:626-628 (1984).	
	173	Ruth et al., "C-5 sustituted pyrimidine nucleosides. 1. Synthesis of C-5 allyl, propyl, and propenyl uracil and cytosine nucleosides via organopalladium intermediates" *J. Org. Chem. 43*(14):2870-2876 (1978).	
	174	Santi, "Perspectives on the design and biochemical pharmacology of inhibitors of thymidylate synthetase" *J. Med. Chem. 28*(2):103-111 (1980).	
	175	Sastry et al., "Membrane-permeable dideoxyuridine 5'-monophosphate analogue inhibits human immunodeficiency virus infection" *Mol. Pharmacol. 41*:441-445 (1992).	
	176	Sauter et al., "Heterogeneity of *erb*B-2 gene amplification in bladder cancer" *Can. Res. 53*:2199-2203 (1993).	
	177	Schiffer et al., "Crystal structure of human thymidylate synthase: A structural mechanism for guiding substrates into the active site" *Biochem. 34*:16279-16287 (1995).	
	178	Schimke, "Gene amplification in cultured cells" *J. Biol.Chem. 263*(13):5989-5992 (1988).	
	179	Segovia, "*Leishmania* gene amplification: A mechanism of drug resistance" *Annals Tropical Med. Parasitol. 88*(2):123-130 (1994).	
	180	Shepard et al., "Resistance of tumor cells to tumor necrosis factor" *J. Clin. Immunol. 8*(5):333-341 (1988).	
	181	Simon, "Cell biological mechanisms of multidrug resistance in tumors" *PNAS USA 91*:3497-3504 (1994).	
	182	Singh et al., "Studies on the preparation and isomeric composition of 186Re- and 188Re-pentavalent rhenium dimercaptosuccinic acid complex" *Nucl. Med. Commun. 14*:197-203 (1993).	
	183	Slamon et al., "Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/*neu* oncogene" *Science 235*:177-182 (1987).	
	184	Slamon et al., "Studies of the HER-2/*neu* proto-oncogene in human breast and ovarian cancer" *Science 244*:707-712 (1989).	
	185	Smith et al., "Regulation and mechanisms of gene amplification" *Phil. Trans. Royal Soc. Lond. B 347*:49-56 (1995).	
	186	Snydman et al., "Analysis of trends in antimicrobial resistance patterns among clinical isolates of *Bacteroides fragilis* group species from 1990 to 1994" *Clin. Infectious Diseases 23*(Suppl. 1):S54-S65 (1996).	
	187	Staschke, K.A. et al. "The in vitro anti-hepatitis B virus activity of FIAU [1-(2'-deoxy-2'-fluro-1-β-D-arabinofuranosyl-5-iodo)uracil] is selective, reversible, and determined, at least in part, by the host cell" Antiviral Res. 23:45-61 (1994)	
	188	Stout et al., "Structure-based design of inhibitors specific for bacterial thymidylate synthase" *Biochem. 38*:1607-1617 (1999).	
	189	Stühlinger et al., "Clinical therapy and HER-2 oncogene amplification in breast cancer: Chemo-vs radiotherapy" *J. Steroid Biochem. Molec. Biol. 49*(1):39-42 (1994).	
	190	Sugarman et al., "Recombinant human tumor necrosis factor-I: Effects on proliferation of normal and transformed cells in vitro" *Science 230*(4728):943-945 (1985).	
	191	Sukumar et al., "Specific patterns of oncogene activation in transplacentally induced tumors" *PNAS USA 87*:718-722 (1990).	

! Month of publication data is unavailable for this citation.

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	192 !	Takeishi et al., "Nucleotide sequence of a functional cDNA for human thymidylate synthase" *Nucl. Acid Res. 13*(6):2035-2043 (1985).	
	193 !	Tannock, "Treatment of cancer with radiation and drugs" *J. Clin. Oncol. 14*(12):3156-3174 (1996).	
	194 !	Tennant et al., "Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection" *Hepatol. 28*(1):179-191 (1998).	
	195 !	Tolstikov et al., "Synthesis and DNA duplex stabilities of oligonucleotides containing C-5-(3-methoxypropynyl)-2'-deoxyuridine residues" *Nucleosides Nucleotides 16*(3):215-225 (1997).	
	196 !	Troutner, "Chemical and physical properties of radionuclides" *Nucl. Med. Biol. 14*(3):171-176 (1987).	
	197 !	Ubeda et al., "The large subunit of the DNA replication complex C (DSEB/RF-C140) cleaved and inactivated by caspace-3 (CPP32/YAMA) during fas-induced apoptosis" *J. Biol. Chem. 272*(31):19562-19568 (1997).	
	198 !	Valette et al., "Decomposition pathways and *in vitro* HIV inhibitory effects of isoddA pronucleotides: Toward a rational approach for intracellular delivery of nucleoside 5'-monophosphates" *J. Med. Chem. 39*:1981 (1996).	
	199 !	Van de Vijver et al., "Amplification of the *neu* (c-*erbB*-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-*erbA* oncogene" *Mol. Cell. Biol. 7*(5):2019-2023 (1987).	
	200 !	Volm et al., "Relationship of inherent resistance to doxorubicin, proliferative activity and expression of P-glycoprotein 170, and glutathione S-transferase-X in human lung tumors" *Cancer 70*(4):764-769 (1992).	
	201 !	Wahba et al., "Direct spectrophotometric evidence for the oxidation of tetrahydrofolate during the enzymatic synthesis of thymidylate" *J. Biol. Chem. 236*(3):C11-C12 (1961).	
	202 !	Wang et al., "Identification and characterization of Ich-3, a member of the interleukin-1J converting enzyme (ICE)/Ced-3 family and an upstream regulator of ICE" *J. Biol. Chem. 271*(34):20580-20587 (1996).	
	203 !	Wataya et al., "Trans-5-(3,3,3-trifluoro-1-propenyl)-2'-deoxyuridylate: A mechanism-based inhibitor of thymidylate synthetase" *J. Med. Chem. 22*(4):339-340 (1979).	
	204 !	Wettergren et al., "Drug-specific rearrangements of chromosome 12 in hydroxyurea-resistant mouse SEWA cells: Support for chromosomal breakage model of gene amplification" *Somatic Cell Mol. Genet. 20*(4):267-285 (1994).	
	205 !	Yen et al., "Characterization of a hydroxyurea-resistant human KB cell line with supersensitivity to 6-thioguanine" *Can. Res. 54*:3686-3691 (1994).	
	206 !	Yin et al., "Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles" *Cell 70*:937-948 (1992).	
	207 !	Zhou et al., "Target protease specificity of the viral serpin CrmA" *J. of Biol. Chem. 272*(12):7797-7800 (1997).	

! Month of publication data is unavailable for this citation.

Examiner's Signature	L. E. Crane	Date Considered	08/20/02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

A# #3

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form1449A-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known	
Application Number	**09/782,721**
Filing Date	**February 12, 2001**
First Named Inventor	**H. Michael SHEPARD**
Art Unit	1623 ~~1653~~
Examiner Name	**L. Crane**
Attorney Docket Number	**NB 2004.02**

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Document Number – Number – Kind Code[2] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
LC	B 1	US-4,668,777	05-26-87	Caruthers et al.	
LC	B 2	US-4,963,263	10-16-90	Kauver	
LC	B 3	US-4,963,533	10-16-90	De Clercq et al.	
LC	B 4	US-5,116,822	05-26-92	De Clercq et al.	
LC	B 5	US-5,133,866	07-28-92	Kauver	
LC	B 6	US-5,137,724	08-11-92	Balzarini et al.	
LC	B 7	US-5,217,869	06-08-93	Kauver	
LC	B 8	US-5,300,425	04-05-94	Kauver	
LC	B 9	US-5,338,659	08-16-94	Kauver, et al.	
LC	B 10	US-5,430,148	07-04-95	Webber, et al.	
LC	B 11	US-5,433,955	07-18-95	Bredehorst et al.	
LC	B 12	US-5,516,631	05-14-96	Frisch	
LC	B 13	US-5,527,900	06-18-96	Balzarini et al.	
LC	B 14	US-5,596,018	01-21-97	Baba et al.	
LC	B 15	US-5,733,896	03-31-98	Holý et al.	
LC	B 16	US-5,968,910	10-19-99	Balzarini	
LC	B 17	US-6,057,305	05-02-00	Holý et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document – Country Code[3] – Number[4] – Kind Code[5] (if known)	Publication Date MM-DD-YY	Name of Patentee or Application of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
LC	B 18	DE 32 29 169 A1	02-09-84	De Clercq et al.		
LC	B 19	EP 0 311 107 A2	04-12-89	Stichting REGA VZW		
LC	B 20	EP 0 311 108A2	04-12-89	Stichting REGA VZW		
LC	B 21	EP 0 316 592	05-24-89	Stichting REGA VZW		
LC	B 22	WO 90/03978	04-19-90	Stichting REGA VZW		
LC	B 23	WO 92/19767	11-12-92	Terrapin Technologies, Inc.		

Examiner's Signature	L. E. Crane	Date Considered	08/15/02

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Aff. #13

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B-PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 2

Complete if Known	
Application Number	09/782,721
Filing Date	February 12, 2001
First Named Inventor	H. Michael SHEPARD
Art Unit	1623 ~~1653~~
Examiner Name	L. Crane
Attorney Docket Number	NB 2004.02

FOREIGN PATENT DOCUMENTS

	B 24	WO 95/09865	04-13-95	Terrapin Technologies, Inc.		
	B 25	WO 96/40739	12-19-96	Terrapin Technologies, Inc.		
	B 26	WO 97/25342	07-17-97	Terrapin Technologies, Inc.		
	B 27	WO 97/49717	12-31-97	Balzarini et al.		
	B 28	WO 98/49177	11-05-98	University College Cardiff Consultants Limited		
	B 29	WO 00/18755	04-06-00	University College Cardiff Consultants Limited and Rega Foundation		
	B 30	WO 01/83501	11-08-01	University College Cardiff Consultants Limited and Rega Foundation		
	B 31	WO 01/85749	11-15-01	University College Cardiff Consultants Limited and Rega Foundation		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published	T[2]
	C 1 !	BAJETTA, E. et al. "A pilot safety study of capecitabine, a new oral fluoropyrimidine, in patients with advanced neoplastic disease" *Tumor* (1996) **82**:450-452	
	C 2 !	CODERRE, J.A. et al. "Mechanism of action of 2',5-difluoro-1-arabinosyluracil" *J. Med. Chem.* (1983) **26(8)**:1149-1152	
	C 3	MEAD, J.A.R. et al. "Pharmacologic aspects of homofolate derivatives in relation to amethopterin-resistant murine leukemia" *Cancer Res.* (November 1966) **26(1)**:2374-2379 (November, 1966).	
	C 4	NICHOL, C.A. and M.T. HAKALA "Comparative growth-inhibitory activity of homofolic ald against cell lines sensitive and resistant to amethopterin" *Biochem. Pharmacol.* (October 1966) **15(10)**:1621-1623 (October, 1966).	
	C 5 !	RODE, W. "Specificity of thymidylate synthase inactivation by 4,5-bisubstituted dUMP analogues" M. Nencki Inst. Exp. Biol., *Acta Biochimica Polonica* (1993) **40(3)**:363-368	
	C 6 !	SATYAM, A. et al. "Design, synthesis, and evaluation of latent alkylating agents activated by glutathione s-transferase" *J. Med. Chem.* (1996) **39**:1736-1747	
	C 7	WATAYA, Y. et al. "Interaction of thymidylate synthetase with 5-nitro-2'-deoxyuridylate" *J. Biol. Chem.* (June 1980) **255(12)**:5538-5544	

Examiner's Signature	L. E. Crane	Date Considered	08/15/02

! Month of publication could not be determined from the copy supplied.

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

+ Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to compete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.